Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.

ARRAY BIOPHARMA INC Exhibit
EX-99.1 2 v474905_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1   Phase 3 COLUMBUS Part 2 Results in BRAF-Mutant Melanoma Presented at European Society for Medical Oncology Congress – Median PFS for patients on combination of binimetinib (45 mg) plus encorafenib (300 mg) was 12.9 months versus 9.2 months for patients on encorafenib (300 mg) – – Generally well-tolerated and safety profile consistent with COLUMBUS Part 1 results –  – New Drug Applications (NDAs) were submitted to the FDA and Marketing Authorization Applications (MAAs) are under review with the EMA for binimetinib and encorafenib in BRAF-mutant advanced melanoma –BOULDER,…
To view the full exhibit click here

About Array BioPharma Inc. (NASDAQ:ARRY)

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.